{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-001502","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.211955+00:00","generated_at":"2026-05-16T11:41:29.920071+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jade Biosciences reports $336M cash; outlines 2026 pipeline milestones including JADE101 Phase 2","bullets":["Cash, cash equivalents and investments ~$336M as of Dec 31, 2025; funds operations into H1 2028.","JADE101 Phase 1 interim data expected H1 2026; Phase 2 in IgAN to start mid-2026 with preliminary data in 2027.","JADE201 (anti-BAFF-R) first-in-human study in RA expected Q2 2026; interim data in 2027.","JADE301 nominated; preclinical; Phase 1 expected H1 2027; details disclosed H2 2026.","Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-001502","json":"https://secwatch.observer/filing/0001193125-26-001502.json","markdown":"https://secwatch.observer/filing/0001193125-26-001502.md","text":"https://secwatch.observer/filing/0001193125-26-001502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526001502/0001193125-26-001502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526001502/d93206d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:41:29.920071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}